Free Trial

Scotiabank Downgrades Sage Therapeutics (NASDAQ:SAGE) to Hold

Sage Therapeutics logo with Medical background

Scotiabank cut shares of Sage Therapeutics (NASDAQ:SAGE - Free Report) from a strong-buy rating to a hold rating in a research report released on Tuesday morning, Marketbeat.com reports. The brokerage currently has $9.20 price objective on the biopharmaceutical company's stock, down from their previous price objective of $12.00.

A number of other research analysts have also recently commented on the stock. Bank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 target price on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research note on Monday, June 16th. Wall Street Zen downgraded shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th. Canaccord Genuity Group upped their price target on shares of Sage Therapeutics from $8.00 to $8.50 and gave the company a "hold" rating in a report on Tuesday, June 17th. Finally, Piper Sandler downgraded shares of Sage Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $9.00 to $8.50 in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a sell rating and sixteen have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $8.75.

Get Our Latest Research Report on SAGE

Sage Therapeutics Stock Down 0.1%

Shares of NASDAQ:SAGE traded down $0.01 during midday trading on Tuesday, reaching $9.20. The company's stock had a trading volume of 1,467,212 shares, compared to its average volume of 1,314,912. The firm has a market cap of $575.79 million, a price-to-earnings ratio of -1.59 and a beta of 0.29. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $13.47. The business has a 50 day moving average price of $7.62 and a 200 day moving average price of $7.31.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.99% and a negative net margin of 747.63%. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same period last year, the company posted ($1.80) EPS. The business's revenue for the quarter was up 78.0% on a year-over-year basis. Sell-side analysts anticipate that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SAGE. Caligan Partners LP acquired a new position in shares of Sage Therapeutics in the 4th quarter valued at about $16,575,000. TIG Advisors LLC bought a new stake in Sage Therapeutics in the 1st quarter valued at about $21,722,000. Boothbay Fund Management LLC bought a new stake in Sage Therapeutics in the 4th quarter valued at about $7,540,000. ADAR1 Capital Management LLC lifted its position in Sage Therapeutics by 3,767.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 742,495 shares of the biopharmaceutical company's stock valued at $5,903,000 after purchasing an additional 723,295 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Sage Therapeutics in the 1st quarter valued at about $4,757,000. 99.22% of the stock is owned by institutional investors and hedge funds.

About Sage Therapeutics

(Get Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Read More

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Should You Invest $1,000 in Sage Therapeutics Right Now?

Before you consider Sage Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.

While Sage Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines